Mediclinic International welcomes Inga Beale to its Board as Independent Director and Chair designate

– SOUTH AFRICA, Stellenbosch –  Mediclinic International Plc (LON: MDC | JSE: MEI NSX: MEP), a leading international private healthcare services group, today announced the appointment of Dame Inga Beale as an independent non-executive director and Chair Designate with effect from 26 March 2020.

Dame Inga has also been appointed as a member of the Nomination Committee with effect from 26 March 2020. Following a handover period, Dame Inga will succeed Dr Edwin Hertzog as Chair upon his retirement at the conclusion of the Company’s annual general meeting on 22 July 2020.

“The Board is delighted to welcome Dame Inga as an independent non-executive director and Chair Designate of the Company. She has a clear understanding of our strong culture and values and will also align readily with our business. Core to these matters are our stakeholder commitment to deliver sustainable high-quality healthcare services and our purpose to enhance the quality of life. Dame Inga will expertly lead the Board in pursuit of these objectives including the challenge if the COVID-19 pandemic continues to spread globally.” said Dr Edwin Hertzog, Chair. 

Alan Grieve, Senior Independent Director, added: “I am very pleased with the outcome of the thorough and independent process conducted to identify a successor to Dr Hertzog. Dame Inga will contribute a wealth of business experience, both as a leader and role model. During her tenure at Lloyd’s of London, she initiated large-scale digital and cultural transformation programmes and led its expansion into Dubai, China and India. Dame Inga also played a critical role in advancing diversity and inclusion initiatives across Lloyd’s and the international insurance sector.”

About Dame Inga

Dame Inga has extensive business management and leadership experience and was appointed in 2014 as the first female Chief Executive Officer of Lloyd’s of London, the insurance and reinsurance market, a position which she held until 2018. She currently serves as an independent member of the global strategy board of Clyde & Co LLP and as an independent non-executive director on the boards of Crawford & Company and London First. In addition, Dame Inga serves on the London Mayor’s Business Advisory Board. She is also Patron of Insuring Women’s Futures and Chair of the UK HIV Commission. During her executive career, she held various senior leadership positions in Switzerland and internationally across the insurance sector, including at Converium, Zurich Insurance Group, Canopius and GE Insurance Solutions.

Dame Inga is a Chartered Insurer and studied economics and accounting. In 2017, she was appointed Dame Commander of the Order of the British Empire for services to the UK economy.

Dame Inga Beale commented: “I am very pleased to be joining Mediclinic International, an organisation that puts patients at the heart of its business. The Group has a clear strategy and exciting long-term outlook under the leadership of Dr Ronnie Van der Merwe and his executive team. I look forward to working with the Board, the executive team and Mediclinic’s various stakeholders as the Company builds on the market-leading positions of its three divisions and adapts to the changing global healthcare environment.”

About Mediclinic International Plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa and the United Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

As at 1 March 2020, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 14-day case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two-day case clinics and three outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 53 hospitals, five sub-acute hospitals and 10-day case clinics across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two-day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company’s primary listing is on the London Stock Exchange in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.